Why the study?
Do atypical antipsychotics offer special advantages or cost-effectiveness compared with conventional anti-psychotic drugs in the treatment of schizophrenia?
Do atypical antipsychotics offer special advantages or cost-effectiveness compared with conventional anti-psychotic drugs in the treatment of schizophrenia?
No takes yet. Share an insight, caveat, or question.
This commentary highlights that large, non-industry-funded trials have confirmed meta-analytic findings showing no special advantages or cost-effectiveness for atypical versus conventional antipsychotics in schizophrenia.
R. Hamish McAllister‐Williams (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: